| scholarly article | Q13442814 |
| P2093 | author name string | Akshay Sharma | |
| Manu Easow Mathew | |||
| Vasumathi Sriganesh | |||
| Ulrike M Reiss | |||
| P2860 | cites work | Gene therapy for haemophilia | Q24187977 |
| Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B | Q24234413 | ||
| LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1 | Q28210584 | ||
| Molecular cloning of a cDNA encoding human antihaemophilic factor | Q28268498 | ||
| Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response | Q29619095 | ||
| Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver | Q33737640 | ||
| Large-scale analysis of adeno-associated virus vector integration sites in normal human cells | Q33930318 | ||
| The gene structure of human anti-haemophilic factor IX. | Q33939512 | ||
| High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. | Q33948828 | ||
| AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. | Q34168942 | ||
| Molecular cloning of the gene for human anti-haemophilic factor IX. | Q34253608 | ||
| A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia | Q34417597 | ||
| Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia | Q34661163 | ||
| Long-term safety and efficacy of factor IX gene therapy in hemophilia B. | Q34783922 | ||
| Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice | Q35621550 | ||
| Adenovirus-associated virus vector-mediated gene transfer in hemophilia B | Q35691659 | ||
| Prospects for gene therapy of haemophilia | Q35824841 | ||
| Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver | Q35848563 | ||
| Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A | Q36000862 | ||
| The tragic history of AIDS in the hemophilia population, 1982-1984. | Q36593789 | ||
| Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial | Q36780134 | ||
| Desmopressin for the treatment of haemophilia | Q37049482 | ||
| Venous access in haemophilic children: choice and management | Q37670966 | ||
| Current options and new developments in the treatment of haemophilia | Q37841547 | ||
| Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges | Q37866086 | ||
| Gene therapy for haemophilia: a long and winding road. | Q37903924 | ||
| Changing paradigm of prophylaxis with longer acting factor concentrates | Q38206858 | ||
| Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion | Q38520320 | ||
| 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases | Q39433082 | ||
| HIV infection in haemophilia--a European cohort | Q41849874 | ||
| Walk a mile in the moccasins of people with haemophilia | Q43481488 | ||
| Production of human factor IX in animals by genetically modified skin fibroblasts: potential therapy for hemophilia B. | Q44190240 | ||
| A new high-potency glycine-precipitated antihemophilic factor (AHF) concentrate. Treatment of classical hemophilia and hemophilia with inhibitors | Q44452614 | ||
| Hepatitis and Clotting-Factor Concentrates | Q45857133 | ||
| Neonatal or hepatocyte growth factor-potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B. | Q45857835 | ||
| Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. | Q45858690 | ||
| Clinical use of a new glycine-precipitated antihemophilic fraction | Q45859062 | ||
| Generalized lymphadenopathy and T cell abnormalities in hemophilia A | Q45861456 | ||
| Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A | Q45868121 | ||
| Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. | Q45875309 | ||
| Merry christmas for patients with hemophilia B. | Q45875659 | ||
| Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. | Q45877779 | ||
| Gene therapy for haemophilia B. | Q45879900 | ||
| Hepatitis C antibody and chronic liver disease in haemophilia | Q45881803 | ||
| Characterization of the human factor VIII gene | Q48385931 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hemophilia | Q134003 |
| P304 | page(s) | CD010822 | |
| P577 | publication date | 2016-12-20 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Gene therapy for haemophilia | |
| P478 | volume | 12 |
| Q92464961 | Navigating Speed Bumps on the Innovation Highway in Hemophilia Therapeutics |
| Q55090825 | Recombinant adenovirus expressing a dendritic cell-targeted melanoma surface antigen for tumor-specific immunotherapy in melanoma mice model. |
| Q64375090 | Viral Vector-Based Delivery of CRISPR/Cas9 and Donor DNA for Homology-Directed Repair in an In Vitro Model for Canine Hemophilia B |
Search more.